Toggle Nav
mobile icon
My Cart
Close
  • Menu
  • Setting
  • Home
  • Signaling Pathways

Signaling Pathways

8 Items

per page
  1. Lapatinib Ditosylate
    A3967 Lapatinib Ditosylate
    Target: EGFR|ErbB-2
    Summary: EGFR/HER2 inhibitor,potent and selective
      ≥24.3 mg/mL
  2. Lapatinib
    A8218 Lapatinib
     2 Citation
    Target: ErbB
    Summary: EGFR/HER2 inhibitor,potent,selective and reversible
      ≥29.05 mg/mL
  3. Afatinib (BIBW2992)
    A8247 Afatinib (BIBW2992)
     1 Citation
    Target: EGFR
    Summary: Irreversible EGFR/HER2 inhibitor
      ≥24.3 mg/mL
  4. CP-724714
    A2412 CP-724714
    Target: VEGFR|PDGFR|Bcr-Abl|Src|EGFR|c-MET|Insulin Receptors|IRG-1R
    Summary: HER2 inhibitor,potent and selective
      ≥23.5 mg/mL
  5. AC480 (BMS-599626)
    A2822 AC480 (BMS-599626)
    Target: EGFR
    Summary: HER1/2 inhibitor,selective and efficacious
      ≥28.35 mg/mL
  6. Mubritinib (TAK 165)
    B1543 Mubritinib (TAK 165)
    Target: ErbB
    Summary: Potent inhibitor of HER2/ErbB2
      insoluble in H2O; ≥76.9 mg/mL
  7. CUDC-101
    A4092 CUDC-101
     1 Citation
    Target: Histone Deacetylases (HDACs)|EGFR|ErbB
    Summary: Multitargeted HDAC inhibitor
      ≥21.7 mg/mL
  8. Afatinib dimaleate
    A3145 Afatinib dimaleate
    Target: EGFR|HER2
    Summary: EGFR inhibitor
      ≥35.9 mg/mL

8 Items

per page